Genetic screening for genetic cancer - a "map" for a healthy future
Genetic screening for cancer (https://medlatec.vn/tin-tuc/bac-si-van-chi-tiet-nghiem-gen-ung-thu-la-gi-s58-n26474) is a method of using gene Decoding technology to detect pathogens that can increase the risk of cancer.
These changes often appear in genes that play an important role in controlling cell growth and division. When these genes are defective, the risk of uncontrolled cell growth and the formation of malignant tumors will increase.
Some studies have shown that about 5-10% of cancer cases are related to genetic factors. A person with a genetic cancer mutation may not show obvious symptoms for many years, but the risk of developing cancer is significantly higher than a person without a vitamin vitamin vitamin vitamin vitamin. In particular, cancers such as breast cancer, ovarian cancer, colon - rectal cancer, pancreas, thyroid disease are often noted for having obvious genetic properties.
MSc. Dr. Nguyen Ba Son - Head of the Genetics Department, MEDLATEC Testing Center said the important significance of screening for genetic cancer:
- Predicted personal risk of hereditary cancers.
- Support your doctor in developing a monitoring, screening and early intervention regimen before the disease shows signs.
Providing information to family members about genetic risks.
- Optimizing treatment and prevention options for people with genetic changes.
Who should get tested for the gene that causes heritable cancer?
Every person can screen for cancer-causing genes to proactively control their health, clearly understand the risks for timely prevention.
However, some of the following groups of subjects are at high risk and should be considered for early implementation, including:
- People with a family history of cancer, especially if diagnosed at a young age (under 50 years old), or having 2 or more relatives with the same type of cancer.
- Women with relatives who have had breast, ovarian, and endometriosis cancers, especially if they are related to the BRCA1 and BRCA2 genes.
- People of ethnic groups with high genetic risk (People of Ashkenazi ethnic group, which have a higher rate of carcinogenicity than the general population).
- People who have had a type of cancer and want to check whether they have a genetic link that increases the risk of recurrence, or have another cancer.
- Parents with young children want to assess the genetic risk of cancer early, in order to develop a suitable screening roadmap.
Oncosure Plus Test - Decoding 145 cancer risk gene breakthroughs with modern sequelae technology
In the list of genetic tests, Oncosure Plus testing is one of the comprehensive and advanced methods, helping to screen for 30 types of genetic cancers.
Oncosure Plus is a test using next-generation generation generation protein sequencing (Next generation Sequencing - NGS) technology to analyze 145 gene mutations that have been studied to be linked to hereditary cancers. Thanks to its accuracy and wide coverage, this test can assess the risk of cancers such as:
- Breast, ovarian, endometriosis cancer - related to the BRCA1, BRCA2, PTEN gene.
- Colon - rectal, stomach, small intestine cancer - related to the genes APC, MLH1, MSH2, PMS2.
- Skin cancer (hex Notch), lung, thyroid, liver, duodenum, prostate, bladder.
- Rare cancers such as: atherosclerosis sarcoma, neuroblastoma, retina, multi-tertial tumor, neuroblastoma, adrenal coronary tumor...
After the blood sample is collected and sent to the testing room, the result will be returned within 15 working days after receiving the sample (excluding Saturdays, Sundays and holidays). The results are consulted by a team of leading experts and genetic doctors, ensuring accuracy and ease of understanding for customers.
Currently, Oncosure Plus testing is being implemented in the MEDLATEC Health System, a unit applying modern gene expression technology in Vietnam. This is the first medical facility to simultaneously possess two strict international quality management certificates in the field of CAP testing (USA) and ISO 15189:2022, ensuring accurate, safe and reliable results.
On the occasion of Vietnamese Family Day (June 28), from now until June 30, 2025, MEDLATEC Health System will give away 2,000,000 VND when customers register for 1 of 3 cancer screening gene tests (Spot-Mas, spot-Mas 10, Oncosure Plus). The program applies to all customers who receive medical examination and treatment at the Hospital/Clinic system, or use on-site testing sample collection services nationwide.
For detailed cancer screening gene testing, people please refer to the details HERE (https://medlatec.vn/tin-tuc/medlatec-tang-ngay-2-000-vnd-khi-xet-nghiem-gen-tam-soat-ung-thu-mon-qua-suc-khoe-danh-rieng-ngay-gia-dinh-viet-nam).
From now until June 30, 2025, MEDLATEC will launch a great incentive program with many health gifts worth up to millions of VND, detailed as follows:
- DO away 2,000,000 VND when registering for 1 of 3 cancer screening gene tests (Spot-Mas, spot-Mas 10, Oncosure Plus).
- DO away 1,000,000 VND when registering for an in-depth home health check-up package - Check 38 health categories and find cancer markings for women.
- GREEN 15% when checking your health periodically at home, assessing the risk of stroke.
- send a detector for colorectal cancer screening (CEA) and see a specialist.
In addition, from now until July 30, 2025, MEDLATEC offers attractive incentives to help customers and their families have the opportunity to protect healthy liver leaves:
- MIEN AST, ALT testing.
- full-APRence abdominal ultrasound.
For any contact and registration information, please call the hotline 1900 56 56 56, or register here (https://medlatec.vn/tin-tuc/ngay-gia-dinh-viet-nam-nhan-con-mua-qua-tang-tu-medlatec).
